EIP
BVS icon

Ellis Investment Partners’s Bioventus BVS Stock Holding History

Ellis Investment Partners’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-500
Closed -$7K – 798
2021
Q3 		$7K Sell
500
-500
-50% -$7.69K ﹤0.01% 645
2021
Q2 		$17K Buy
+1,000
New +$16.1K ﹤0.01% 536

Other funds holding BVS

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
JIC
Juniper Investment Company New York $378M AUM 95.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NI
Nuance Investments Kansas City, Missouri $588M AUM 6.93% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

Ellis Investment Partners's BVS Position: Q4 2021 in Review

Ellis Investment Partners sold out of Bioventus (BVS) in Q4 2021, closing a stake of 500 shares — an estimated $7K sold.

Ellis Investment Partners first reported a position in BVS in Q2 2021 and held it in 2 quarters. The position peaked at $17K in Q2 2021. 98 funds tracked by Wall St. Rank hold BVS as of Q4 2021.

  • Ellis Investment Partners reported no remaining Bioventus position as of Q4 2021 after selling out during the quarter.
  • Ellis Investment Partners sold 500 Bioventus shares in Q4 2021, an estimated $7K.
  • Ellis Investment Partners first reported a position in Bioventus in Q2 2021 and held it in 2 quarters.
  • Ellis Investment Partners's Bioventus position peaked at $17K in Q2 2021.
  • 98 funds tracked by Wall St. Rank held Bioventus as of Q4 2021.

Based on Ellis Investment Partners's 13F filing for Q4 2021, filed 1 Feb 2022.